Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therap...

Full description

Saved in:
Bibliographic Details
Main Authors: Shodai Kawanami, Yasuyuki Egami, Masaru Abe, Mizuki Osuga, Hiroaki Nohara, Kohei Ukita, Akito Kawamura, Koji Yasumoto, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Masami Nishino
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:ESC Heart Failure
Subjects:
acute decompensated heart failure
dapagliflozin
diuretics
worsening renal function
Online Access:https://doi.org/10.1002/ehf2.15212
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15212

Similar Items